Compugen (CGEN) Metrics: History & Chart

Compugen Ltd.(CGEN)

Biotechnology · Holon, TA

$2.32+0.01 (+0.43%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Compugen Ltd.

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.

Holon, TA

75 employees

cgen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eran Ophir

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-0.86%
30D Total Return	-10.81%
YTD Total Return	+50.98%
1Y Total Return	+41.72%
3Y Total Return	+159.85%
5Y Total Return	-63.79%
10Y Total Return	-62.81%
15Y Total Return	-44.68%
20Y Total Return	-16.88%

2026	+50.98%
2025	0.00%
2024	-22.73%
2023	+176.65%
2022	-83.36%
2021	-64.49%
2020

CAGR TTM	+41.48%
CAGR 3Y	+37.47%
CAGR 5Y	-18.39%
CAGR 10Y	-9.42%
CAGR 15Y	-3.87%
CAGR 20Y	-0.92%

PE Ratio	6.15
PE Ratio Avg TTM	6.53
PE Ratio Avg 3Y	42.60
Current VS TTM Avg	-5.85%
Current VS 3Y Avg	-85.56%
Current VS 5Y Avg	-85.56%

All Metrics

CGEN Valuation Metrics

CGEN Stock Price Metrics

CGEN Dividend Metrics

CGEN Growth Rate Metrics

CGEN Discounted Cash Flow Metrics

CGEN Returns By Period

CGEN Yearly Returns

CGEN Average Annual Returns By Period (CAGR)

CGEN Revenue Metrics

CGEN PE Ratio Metrics

CGEN PS Ratio Metrics

CGEN PB Ratio Metrics

CGEN Price to Free Cash Flow Ratio Metrics

CGEN Debt to Equity Ratio Metrics

CGEN PEG Ratio Metrics

CGEN FCF Yield

CGEN Earnings Yield

CGEN EBITDA Yield

CGEN OCF Yield

CGEN EV/EBIT Ratio Metrics

CGEN EV/EBITDA Ratio Metrics

CGEN EV/Assets Ratio Metrics

CGEN EV/Sales Ratio Metrics

CGEN Current Ratio Metrics

CGEN Quick Ratio Metrics

CGEN ROIC Metrics

CGEN Return on Assets Metrics

CGEN Return on Equity Metrics

CGEN Net Profit Margin Metrics

CGEN Gross Profit Margin Metrics

CGEN Tax Rate Metrics

PS Ratio	2.95
PS Ratio Avg TTM	9.59
PS Ratio Avg 3Y	4.61
Current VS TTM Avg	-69.22%
Current VS 3Y Avg	-36.00%
Current VS 5Y Avg	-77.30%

PB Ratio	2.46
PB Ratio Avg TTM	2.85
PB Ratio Avg 3Y	2.77
Current VS TTM Avg	-13.64%
Current VS 3Y Avg	-11.14%
Current VS 5Y Avg	+5.07%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.03
Debt/Equity Ratio Avg TTM	0.04
Debt/Equity Ratio Avg 3Y	0.04
Current VS TTM Avg	-22.55%
Current VS 3Y Avg	-19.10%
Current VS 5Y Avg	-5.07%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	16.25%
Earnings Yield Avg TTM	15.50%
Earnings Yield Avg 3Y	9.57%
Current VS TTM Avg	+4.86%
Current VS 3Y Avg	+69.88%
Current VS 5Y Avg	+69.88%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	6.98
Ev/Ebit Ratio Avg TTM	6.31
Ev/Ebit Ratio Avg 3Y	9.86
Current VS TTM Avg	+10.70%
Current VS 3Y Avg	-29.21%
Current VS 5Y Avg	-29.21%

Ev/Ebitda Ratio	6.98
Ev/Ebitda Ratio Avg TTM	6.31
Ev/Ebitda Ratio Avg 3Y	9.83
Current VS TTM Avg	+10.70%
Current VS 3Y Avg	-29.02%
Current VS 5Y Avg	-29.02%

Ev/Assets Ratio	1.53
Ev/Assets Ratio Avg TTM	1.46
Ev/Assets Ratio Avg 3Y	1.32
Current VS TTM Avg	+4.95%
Current VS 3Y Avg	+15.53%
Current VS 5Y Avg	+29.43%

Ev/Sales Ratio	2.86
Ev/Sales Ratio Avg TTM	9.07
Ev/Sales Ratio Avg 3Y	3.65
Current VS TTM Avg	-68.47%
Current VS 3Y Avg	-21.67%
Current VS 5Y Avg	-68.34%

Current Ratio	5.72
Current Ratio Avg TTM	5.53
Current Ratio Avg 3Y	5.16
Current VS TTM Avg	+3.46%
Current VS 3Y Avg	+10.73%
Current VS 5Y Avg	-4.89%

Quick Ratio	5.72
Quick Ratio Avg TTM	5.53
Quick Ratio Avg 3Y	5.16
Current VS TTM Avg	+3.46%
Current VS 3Y Avg	+10.73%
Current VS 5Y Avg	-4.89%

ROIC	26.14%
ROIC Avg 3Y	(12.42%)
ROIC Avg 5Y	(22.23%)
Current VS 3Y Avg	+310.48%
Current VS 5Y Avg	+217.56%
Current VS 10Y Avg	+172.64%

ROA	25.43%
ROA Avg TTM	2.39%
ROA Avg 3Y	(5.52%)
Current VS TTM Avg	+963.10%
Current VS 3Y Avg	+560.61%
Current VS 5Y Avg	+466.08%

ROE	39.66%
ROE Avg TTM	1.81%
ROE Avg 3Y	(17.32%)
Current VS TTM Avg	+2087.37%
Current VS 3Y Avg	+329.03%
Current VS 5Y Avg	+209.92%

Net Profit Margin	47.55%
Net Profit Margin Avg TTM	(298.08%)
Net Profit Margin Avg 3Y	(192.30%)
Current VS TTM Avg	+115.95%
Current VS 3Y Avg	+124.73%
Current VS 5Y Avg	+137.77%

Gross Profit Margin	86.89%
Gross Pft Margin Avg TTM	17.54%
Gross Pft Margin Avg 3Y	31.11%
Current VS TTM Avg	+395.52%
Current VS 3Y Avg	+179.32%
Current VS 5Y Avg	+214.56%

Tax Rate	0.00%
Tax Rate Avg 3Y	42.01%
Tax Rate Avg 5Y	42.01%
Current VS 3Y Avg	-100.00%
Current VS 5Y Avg	-100.00%
Current VS 10Y Avg	-100.00%